Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1LG2 | Q9BQ51 | 2/20 | 0.50 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.50 |
| ▸ | ECE1 | P42892 | 3/20 | 0.47 |
| ▸ | BACE1 | P56817 | 10/20 | 0.45 |
| ▸ | CTSD | P07339 | 4/20 | 0.45 |
| ▸ | VSIR | Q9H7M9 | 2/20 | 0.38 |
| ▸ | CTSC | P53634 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30974352 | 0.93 | CD274 (0.57) | PDCD1LG2CD274ECE1BACE1CTSD | |
| SCHEMBL31121649 | 0.91 | ECE1 (0.49) | PDCD1LG2CD274ECE1BACE1CTSD | |
| SCHEMBL30165201 | 0.90 | ENPEP (0.43) | PDCD1LG2CD274BACE1CTSDCTSC | |
| SCHEMBL29630775 | 0.89 | ECE1 (0.54) | PDCD1LG2CD274ECE1BACE1CTSD | |
| SCHEMBL29630874 | 0.89 | ECE1 (0.54) | PDCD1LG2CD274ECE1BACE1CTSD | |
| SCHEMBL29630884 | 0.89 | ECE1 (0.54) | PDCD1LG2CD274ECE1BACE1CTSD | |
| SCHEMBL29630710 | 0.89 | ECE1 (0.54) | PDCD1LG2CD274ECE1BACE1CTSD | |
| SCHEMBL29973181 | 0.88 | BACE1 (0.48) | PDCD1LG2CD274ECE1BACE1CTSD | |
| SCHEMBL29355062 | 0.87 | ECE1 (0.50) | PDCD1LG2CD274ECE1BACE1CTSD | |
| SCHEMBL29658150 | 0.87 | CD274 (0.52) | PDCD1LG2CD274ECE1BACE1CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113861268-B | Cell penetrating peptides and methods of making and using the same | 恩特拉达治疗学股份有限公司 | 2025-04-01 | — | — | CN | disclosed |
| US-20250011367-A1 | CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | ENTRADA THERAPEUTICS, INC. | 2025-01-09 | — | — | US | disclosed |
| US-20220177523-A1 | CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | ENTRADA THERAPEUTICS, INC. | 2022-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011367-A1 | CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | VIP, LNPEP, TAP1 | PDCD1LG2 1212/4885CD274 1640/4885ECE1 1368/4885 |
| US-20220177523-A1 | CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | VIP, LNPEP, TAP1 | PDCD1LG2 1212/4885CD274 1640/4885ECE1 1368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.